Skip to main content
. 2019 Oct 23;11(11):1624. doi: 10.3390/cancers11111624

Figure 11.

Figure 11

Role of AC8 in triple-negative breast cancer (TNBC) cell proliferation. (a) Non-tumoral breast epithelial MCF10A, luminal MCF7 breast cancer, and TNBC cells (MDA-MB-231, BT20, and Hs578T) were lysed and subjected to Western blotting with anti-AC8 antibody, followed by reprobing with anti-β-actin antibody for protein loading control. (b,c) MDA-MB-231 (b) and Hs578T (c) cells were transfected with siAC8#1, siAC8#2, or scramble plasmid (Sc), as indicated. Forty-eight hours later, cell proliferation was assessed for a further 24 and 48 h using the bromodeoxyuridine (BrdU) cell proliferation assay kit, as described in Section 4. The box plot represents cell proliferation 0, 24, and 48 h after cell transfection, presented as BrdU uptake rate; * p < 0.05 compared to the corresponding control (cells transfected with scramble plasmid). (c, top panel) Hs578T cells were lysed and subjected to 10% SDS-PAGE and Western blotting with anti-AC8 antibody. Blots are representative of three separate experiments.